GTB-3650 Tri-Specific Killer Engager (TriKE®)
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 45 patients (estimated)
- Sponsors
- University of Minnesota - Masonic Cancer Center
- Tags
- CD16, CD33, Interleukin 15 (IL-15)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2021
- NCT Identifier
- NCT06594445
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.